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Abstract 
Clostridium difficile is a Gram-positive, spore-forming bacterium that continues to present a 
world-wide problem in healthcare settings. The bacterium causes disease, the symptoms of 
which include diarrhoea, fever, nausea, abdominal pain and even death. Despite the 
prevalence of the disease, the diagnosis of C. difficile infection is still challenging, with a 
variety of methods available, each varying in their effectiveness. In this work we sought to 
identify a new biomarker for C. difficile, develop affinity reagents and design a diagnostic 
assay for C. difficile infection which could be used in a typical two-step testing algorithm. 
Initially a bioinformatics pipeline was developed that identified a surface associated 
biomarker “AKDGSTKEDQLVDALA” present in all C. difficile strains sequenced to-date and 
unique to the C. difficile species. Monoclonal antibodies were subsequently raised against 
peptides corresponding to the biomarker sequence. During characterisation studies, 
monoclonal antibody 521 (mAb521) was shown to bind all known C. difficile surface layer 
types, but not closely related strains.  Surface plasmon resonance measurements were used 
to calculate an apparent equilibrium dissociation constant of 36.5 nM between the purified 
protein target containing the biomarker (surface layer protein A) and mAb521. We 
demonstrate a limit of detection of 12.4 ng/ml against surface layer protein A and 1.7 x 106 
cells/ml in minimally processed C. difficile cultures.  The utility of this computational approach 
to antibody design for diagnostic tests is the ability to produce antibodies which can act as 
universal species identifiers whilst mitigating the likelihood of false-positive detection by 
intelligently screening potential biomarkers against RefSeq data for other non-target bacteria. 
Introduction 
Clostridium difficile infection (CDI) continues to be a significant economic burden, particularly 
in healthcare settings, with the spectrum of clinical disease ranging from mild diarrhoea to 
death. C. difficile includes both pathogenic (toxin-producing) and non-pathogenic strains, with 
both strains able to colonise their hosts, however only toxin producing strains are associated 
with disease 1.  
The choice of laboratory test for C. difficile is a contentious one with a multitude of tests 
available. One commonly used test is an enzyme immunoassay (EIA) which detects glutamate 
dehydrogenase (GDH), a secreted enzyme found in stool samples during CDI which converts 
L-glutamate into α-ketoglutarate.  This pan-C. difficile antigen can be tested for in a few hours 
using the glutamate dehydrogenase enzyme immunoassay (GDH EIA), however it does not 
determine whether the C. difficile strain is actively producing toxin 2.  To elucidate this, the 
toxins associated with CDI, toxin A/B, are typically assayed using a second EIA, again typically 
taking a few hours to process 3.  More recently, nucleic acid amplification tests (NAAT) have 
been increasingly used for toxin A/B testing 4.  However, when relying solely on molecular 
methods for CDI diagnosis, it has been suggested this results in the over-diagnosis of CDI 
through the detection of asymptomatic carriage, resulting in overtreatment and increased 
healthcare costs 5. The current protocol for testing and diagnosing CDI in the UK is based on 
guidelines from the Department of Health, who advise that organisations adhere to a two-
step testing algorithm which consists of a GDH EIA (or NAAT) measurement to screen samples, 
followed by a toxin A/B EIA 6.  If the first test in the algorithm is negative, the second test does 
not need to be performed.  The authors of the guidelines acknowledge that no test or 
combination of tests is infallible and the clinical condition of the patient should always be 
taken into consideration when making management and treatment choices.   
Rates and severity of CDI in hospitals in Europe and North America have increased since 2000 
and correlate with the dissemination of an epidemic strain, 027, characterised by higher than 
usual toxin A/B production in addition to demonstrating resistance to fluoroquinolone and 
cephalosporin antibiotics 7. Typing studies from 2008 revealed that PCR ribotype 027 was the 
most common strain isolated from symptomatic patients, accounting for over 41.3 % of 
isolates in English hospitals, followed by type 106 (20.2 %) and type 001 (7.8 %) 8. A mixture 
of 44 other PCR ribotypes accounted for the remaining 28.9 % of isolates 8.  More recent data 
from the C. difficile Ribotyping Network indicate that 027 prevalence has decreased in the 
United Kingdom, potentially because of efforts to reduce fluoroquinolone and cephalosporin 
usage 9. 
Although a relatively simple and inexpensive assay, concerns have been raised about the 
sensitivity of the commonly used GDH EIA, particularly for non-027 strains 10. This is not 
because of strain-dependent difference in GDH expression but most likely because 027 strains 
tend to attain higher organism burdens, which means that GDH is easier to detect using the 
GDH EIA as it is present at a greater multiplicity 11. Although the sensitivity of the GDH EIA is 
comparable to PCR for 027 strains, it has been demonstrated that PCR is significantly more 
sensitive than the GDH EIA for detecting strains of ribotypes other than 027 12. Another 
disadvantage of the GDH EIA is that antiserum against C. difficile GDH has the potential to 
cross-react with GDH from other anaerobes 3. Despite the sensitivity and specificity of the 
GDH EIA being inferior to PCR it is still widely used in clinical diagnostic algorithms, because it 
is cheaper and quicker than standard PCR. 
Bearing in mind the current limitations outlined above, we sought to create a new diagnostic 
test for CDI which could act as an alternative to the GDH EIA.  A major hurdle in the 
development of any new medical diagnostic test for infectious disease is the development of 
suitable affinity reagents, such as antibodies, that bind specifically to the target organism. To 
address this challenge, and to find a new specific biomarker for C. difficile, a bioinformatics 
method was developed building on a previously described approach 13. This approach is able 
to predict biomarkers for a given group of bacteria from their genome sequence data. In this 
work we demonstrate the utility of a computational approach for generating species-specific 
C. difficile monoclonal antibodies (mAbs) against a biomarker ubiquitous to all C. difficile 
strains sequenced to-date.  
Materials and Methods 
Biomarker identification in C. difficile using a bioinformatics approach 
There are several idealised requirements for pathogenic biomarkers in a diagnostic setting. 
Firstly, the biomarker must exist in all strains that the diagnostic test is required to identify. 
Secondly, the biomarker must not occur in any other organism; i.e. the biomarker must be 
globally unique to the group of interest in order to avoid false-positive results. Our team 
inserted a third project specific requirement; the biomarker must encode an epitope on the 
surface of the cell in order to be accessible with minimal sample preparation. This rationale 
was inserted, as the biomarker will be more amenable to point of care scenarios if limited 
sample processing is required. 
A custom bioinformatics pipeline building on principles first described by Flanagan and co-
workers was exploited in order to produce a set of putative biomarkers in C. difficile that 
conform to the specific selection criteria outlined above 13.  For a more detailed description 
of the biomarker identification process see Supporting Information.  
Bacterial storage, growth and strains used in this work 
All of the following cultures were grown anaerobically at 37°C using anaerobic jars and 
Anaerocult A gas packs (Merck).  C. difficile strains were plated on C. difficile agar base (Sigma), 
with 7 % sheep’s blood and C. difficile C.D.M.N. – selective supplement (Oxoid) or cultured in 
brain heart infusion (BHI) (Sigma) or cooked meat broth (Sigma). Clostridium sordellii, 
Clostridium perfringens, Peptostreptococcus anaerobius and Enterococcus faecalis were 
cultured in BHI or on soy-tryptone agar (15 g/l tryptone, 5 g/l soytone, 5 g/l NaCl, 15 g/l agar) 
supplemented with 7 % sheep’s blood. Clostridium hiranonis was cultured in PY medium 
(tryptone 5 g/l, peptone (pepsin digested) 5 g/l, yeast 10 g/l, L-cysteine 0.5 g/l, D-glucose 5 
g/l) + 40 ml salt solution (CaCl2.H2O 0.25 g/l, MgSO4 x 7 H2O 0.5 g/l, K2HPO4 1 g/l, KH2PO4 1 
g/l, NaHCO3 10 g/l, NaCl 2 g/l).  Escherichia coli, Pseudomonas aeruginosa, Citrobacter 
freundii, Proteus mirabilis and Klebsiella pneumoniae strains were all cultured aerobically at 
37°C in LB media (bacto-tryptone 10 g/l, yeast 5 g/l, NaCl 10 g/l). 
Strains used to probe for interaction with mAb521 are shown in Table S-1.  The C. difficile 
Oxford strains (Ox) used in this study are representative members from each of the 12 surface 
layer types (SLTs) plus an additional strain, Ox575, which contains a hybrid cassette 
comprising the cwp66 gene of cassette 2 and the secA2 and slpA genes of cassette 6. The Ox 
strains were all kindly donated by Dr Kate Dingle, Nuffield Department of Medicine, Oxford.  
UK. 
Monoclonal antibody production  
Based on the identified biomarker amino acid sequence, linear peptides were synthesised to 
produce mouse mAbs through the hybridoma technique (Abmart).   
Hybridoma culture and production of mAb521 
All cell culture reagents were purchased from Sigma. Hybridoma cells specific for mAb521 
production were grown at 37°C in a 5 % CO2 incubator, in basic media (RPMI 1640, 10 % foetal 
calf serum (FCS) (v/v), 100 mg/l penicillin-streptomycin and 2 mM (w/v) glutamine), initially 
with the addition of 10 % (v/v) Condimed  to aid recovery. Fully confluent cells were then 
grown in media with reducing FCS content until they were able to grow efficiently in serum 
free media (10 %, 5 %, 2 %, 0.5 %, serum free). Large scale growth of the cells was performed 
in specialist media, EX-CELL® 610-HSF Serum-Free Medium for Hybridoma Cells, low-protein 
(11 mg/l), with L-glutamine, to which 100 mg/l penicillin-streptomycin was added. Cells were 
left in this media for 8-10 days until the majority were dead, after which the supernatant was 
recovered by centrifugation at 13,000 g for 10 min.  mAb521 was purified from the 
supernatant using a HiTrap Protein G HP prepacked column (GE Healthcare Life Sciences).  The 
column was equilibrated with 10 column volumes buffer A (20 mM sodium phosphate pH 
7.2).  Sodium phosphate, 100 mM pH 7.2, was added to the culture supernatant at a ratio of 
1:5 (final concentration 20 mM sodium phosphate pH 7.2). A minimum of 260 ml cell culture 
supernatant was loaded on the column before the application of 20 column volumes of buffer 
A.  Finally, mAb521 was eluted with 100 mM glycine/HCl, pH 2.3 in 1 ml fractions collected 
into 100 µl 1 M Tris-HCl pH 8.0 to immediately neutralise the fraction.  
Polyclonal antibody production against purified surface layer protein A 
Surface layer protein A (SlpA) was purified to homogeneity (see Supporting Information) to 
raise polyclonal antibodies in mice (Cambridge Research Biochemicals).  IgG antibody 
fractions were recovered from serum using a Protein A column pre-equilibrated in buffer A.  
Briefly, serum was diluted 1 in 5 using 100 mM sodium phosphate pH 7.2 before loading onto 
a pre-equilibrated Protein A column.  The column was then washed with 10 column volumes 
of buffer A before elution using 100 mM glycine/HCl, pH 2.3, collecting 1 ml fractions into 100 
µl 1 M Tris-HCl pH 8.0.  The resulting IgG polyclonal antibody pool was designated pAbSlpA.  
pAbSlpA was conjugated to HRP using EZ-link Plus Activated HRP (Thermo Fisher) via primary 
amine groups on the antibody according to manufacturer’s instructions. Briefly, 1 mg pAbSlpA 
in 50 mM carbonate buffer pH 9.6 was added to lyophilised activated HRP and incubated for 
1 h at room temperature (RT). Thereafter, 10 µl 5 M sodium cyanoborohydride solution 
(Sigma) was added to the enzyme reaction mix and incubated for 15 min at RT followed by 
the addition of 60 µl 1 M ethanolamine pH 8.5 for 15 min at RT to quench any unreacted 
material. pAbSlpA-HRP was purified by size exclusion using a HiLoad 16/600 Superdex 200 
column, fractions were collected and assessed for antibody binding and HRP activity. 
 
 
SPR measurements 
Prior to SPR, mAb521 and SlpA were dialysed extensively into PBS.  All analyses of 
interactions between mAb521 and SlpA were performed on a BIAcore X100 system 
equipped with a CM5 chip (BIAcore GE Healthcare) at a flow rate of 10 μl/min. For 
immobilization of SlpA, the chip was activated with NHS/EDC (1:1) before injection of SlpA in 
10 mM acetate, pH 4.0 to attain 255 Resonance Units (RU) of binding. This is designated the 
FC2 sample channel. In contrast the FC1 reference channel was NHS/EDC treated and then 
blocked using ethanolamine.   Monoclonal antibody 521 (250 nM – 0.65 nM) was injected 
over both reference and sample surfaces for 300 s before a 600 s wait time followed by a 12 
s regeneration using 10 mM glycine pH 2.0.  Injection of PBS alone served as a negative 
control.  All measurements were performed in duplicate at 25°C in PBS.    The results derived 
from the reference channel FC1 were subtracted from the FC2 sample channel.  SPR data 
was exported and plotted using OriginPro 8.  The responses for each of the different 
antibody concentrations at 380 s were taken and fitted to a sigmoidal fitting function to 
derive the apparent KD. 
  
Results and Discussion 
Biomarker identification in C. difficile using a custom bioinformatics pipeline 
The custom bioinformatics pipeline identified 28 biomarker containing proteins that were 
positive for all surface associated localisation tools (see Supporting Information).  Therefore, 
a total of 28 biomarker containing proteins were predicted to be exposed on the surface of 
C. difficile.  After manual curation and analysis of the 28 biomarker containing proteins, SlpA 
was judged to be the most promising candidate. The surface layer (S-layer), as the name 
suggests, typically forms the outermost structure in the bacteria in which they are produced.  
Functions of the S-layer include cell shape determination, molecular sieving and host cell 
adhesion/invasion 14.  The proteinaceous C. difficile S-layer is encoded by the slpA gene, 
located within the cell wall protein (cwp) gene cluster, which also includes cwp66 (adhesin) 
and secA2 (secretory translocase) 15.  Whole genome sequencing and phylogenetic analysis 
has shown these genes formed a 10-kb cassette, of which 12 distinct surface layer types (SLTs) 
can be identified 16.  Unlike most bacteria whose S-layers are composed of a single protein 
subunit, the S-layer of C. difficile is constructed using two protein subunits, High Molecular 
Weight Surface Layer Protein A (HMW SlpA) and Low Molecular Weight Surface Layer Protein 
A (LMW SlpA) (Figure 1a).  The two subunits are derived from a single polypeptide precursor, 
Surface layer Protein A (SlpA), containing an N-terminal secretion signal 17,18.  The precursor, 
SlpA, is translocated across the cytoplasmic membrane via the accessory Sec system 19, which 
directs the signal peptide across the membrane, where the protein is cleaved by CWP84 
(Figure 1b) into the HMW and LMW subunits 20.  The HMW and LMW SlpA form a 1:1 
heterodimer complex through non-covalent interactions between highly conserved 
sequences 21 in a Ca2+ dependent manner 22. HMW SlpA contains three tandem cell wall 
binding 2 motifs (PF04122) which are suggested to be important in mediating interaction with 
the cell wall, acting as an anchor18. These domains interact with anionic polymer PSII, highly 
conserved in C. difficile strains, to direct the protein to the cell wall 23.  It is estimated that 
there are 590,000 S-layer subunits per cell, requiring synthesis, export and assembly of 164 
subunits per second during exponential growth 18,21.  The S-layer appears to be essential, as 
evidenced by an inability to generate transposon-mediated insertional mutants within the 
slpA gene, consistent with the fact that S-layer proteins have been detected in all C. difficile 
strains to-date 21.  The SlpA biomarker - comprises of 16 amino acids ‘AKDGSTKEDQLVDALA’ 
within the HMW subunit.  SlpA is the most abundant protein in C. difficile, accounting for 10-
15 % of the total cellular protein 19.  Additionally the slpA gene is strongly transcribed during 
the entire growth phase 24.  These two characteristics suggested SlpA is an ideal diagnostic 
candidate. 
The bioinformatics prediction that the biomarker is surface associated is consistent with the 
wider literature.  In the absence of a high-resolution structure of the C. difficile S-layer, it is 
challenging to predict the precise topology of the S-layer, or the surface accessibility of the 
HMW biomarker under native anaerobic conditions. LMW SlpA demonstrates higher inter-
strain variability compared with the HMW subunit 25, exhibiting on average 32 % sequence 
identity between any two strains 21. This suggests a possible role in immune evasion and host 
cell adhesion.  Accordingly, in bacterial adherence studies, testing C. difficile adherence to 
enterocytes, the LMW subunit was found to be more crucial in host-cell attachment than the 
HMW subunit, suggesting LMW is more surface-exposed 26. This is also consistent with a 
HMW: LMW SAXS structure, suggesting HMW is involved in peptidoglycan anchoring 21.  
Conversely, evidence also exists that demonstrates the importance of HMW SlpA in adhesion 
to enterocytes. FACS analysis has shown that antiserum to recombinant HMW completely 
eliminated C. difficile binding to HEp-2 cells and similarly human colon tissue sections 
incubated with LMW and HMW subunits revealed the HMW subunit showed higher levels of 
binding 27.   
Regarding the specific 3D location of the biomarker in the HMW subunit, in the absence of a 
defined crystal structure a suite of bioinformatics tools were used to predict that the 
biomarker was solvent exposed based on amino acid polarity and secondary structure of the 
biomarker.  A total of 8 mAbs were produced based on the SlpA biomarker sequence and 
were screened by ELISA for binding to the biomarker peptide sequence and purified SlpA. Two 
antibodies, mAb521 and mAb652, demonstrated binding to both the peptide sequence and 
purified SlpA, – mAb521 showed the greatest binding, in all screening assays performed (data 
not shown) and was taken forward for characterisation.  
To be able to perform appropriate laboratory controls to assess the specificity of mAb521 
produced against the SlpA biomarker, it was important to identify the species which have 
amino acid sequences which most closely resemble the SlpA biomarker.  BLASTP searches 
using the SlpA biomarker sequence identified C. hiranonis and P. anaerobius as having 
sequences that were the most closely related to SlpA (at the time the BlastP search was 
performed). However, the avalanche of next generation sequencing data deposited in RefSeq, 
on a daily basis, makes bioinformatics results highly dynamic and subject to change on a daily 
basis.  A more recent analysis (July 2018) reveals Clostridium argentinense and Clostridium 
senegalense as the closest SlpA homologs in the form of uncharacterised cell-wall binding 
repeat containing proteins. That said, the two species chosen are very closely related and still 
act as exemplars of the reagent specificity.  In addition to investigating the similarity of the 
SlpA sequence to other proteins, the similarity of full genome sequences to C. difficile was 
also explored.  The Pathosystems Resource Integration Centre (PATRIC) was used to identify 
that C. sordellii was the species most closely related to C. difficile 28.  Thus, C. hiranonis, P. 
anaerobius and C. sordellii served as negative controls for mAb521 screening where 
appropriate. In addition and possibly more importantly, other bacteria commonly found in 
stool samples were also screened against the affinity reagents as negative controls. 
Western blot analysis against whole cell lysates 
Currently, all sequenced C. difficile strains fall into 12 SLTs, which therefore represent the 
known S-layer diversity within the C. difficile species 16. Whole cell lysates of each of the 12 
SLTs plus C. difficile 630 were probed using mAb521 in a Western blot (see Supporting 
information).  Additionally, for completeness, Ox575 was probed for interaction with mAb521 
in the event that the hybrid displayed differential binding to mAb521 than any of the 12 SLTs.  
When analysed by SDS-PAGE, each C. difficile cell lysate displayed the characteristic dual 
banding pattern associated with the presence of HMW SlpA and LMW SlpA (Figure 2).  This is 
in agreement with previous studies which have shown variability in the mobility of the two 
SLPs between different strains 29,30.  mAb521 (5 μg/ml) binds to HMW SlpA within all 12 SLTs 
and not to any other proteins within the negative control strains.  Furthermore, the positive 
binding occurs in one defined band, demonstrating unique specificity of mAb521 to HMW 
SlpA.   
Whole cell direct ELISA binding of mAb521 against all known C. difficile SLTs 
Whole cells of C. difficile 630, the 12 SLTs and Ox575 were tested for interaction with mAb521 
(100 ng/ml) using a whole cell ELISA format (See Supporting Information).  The OD600 nm of 
the cells was kept constant throughout, enabling semi-quantitative comparative analysis of 
mAb521 binding.  The antibody was shown to recognise all 12 SLTs plus Ox575 whilst 
displaying negligible cross-reactivity to the closely related species, C. hiranonis, P. anaerobius 
and C. sordellii (Figure 3).  Additionally, the binding displayed across the C. difficile strains was 
relatively uniform, with a maximal variation of 35 % between the highest (Ox1437a) and the 
lowest (Ox1396) absorbance value.  If Ox1396 is not considered, the binding will be highly 
comparable between all remaining SLTs with a variability of < 5 %. 
Whole cell direct ELISA testing mAb521 against bacteria commonly found in stool samples 
In order to validate that mAb521 did not cross react with other bacteria typically found in 
stool samples, a selection of common faecal bacteria were selected and probed for binding 
to mAb521 using a whole cell ELISA (see supporting information). Agreeably, mAb521 showed 
limited cross reactivity to all the faecal bacteria tested under these conditions. In fact, the 
absorbance values were similar to negative controls in which PBS was added instead of cells 
(Figure 4).  C. difficile 630 was used as a positive control and displayed > 90 % binding 
compared with the highest negative control value of E. faecalis. 
SPR analysis of mAb521 – SlpA interaction 
To calculate the affinity of mAb521 for its target HMW SlpA, SlpA was purified to homogeneity 
(See Supporting Information) before being tethered to a CM5 chip.  The kinetics of the 
interaction could not be reliably calculated due to mass transport effects which were 
consistent under all binding conditions tested (data not shown).  As such, the equilibrium 
dissociation constant for mAb521 binding to SlpA was calculated through duplicate titrations 
of mAb521 (250 nM – 0.65 nM) over SlpA (Figure 5).  The equilibrium dissociation constant 
for mAb521 binding to SlpA was calculated to be 36.5 nM (Figure 5 inset).  This demonstrates 
that mAb521 can recognise the biomarker when it undertakes its native structure as part of 
SlpA and further validates the whole cell binding assays, which demonstrated universal 
binding to native protein in all the SLTs. 
Sandwich ELISA using mAb521 and pAbSlpA 
Initially we planned to use a sandwich ELISA, using mAb521 for both the capture and 
detection of whole C. difficile cells on the premise that the biomarker is surface exposed, 
based on the observations from whole cell direct ELISA data (Figures 3 & 4).  Provided the 
biomarker is indeed surface exposed, whole C. difficile cells should be multivalent with 
respect to the biomarker and therefore should be amenable to capture and detection using 
mAb521.  However, when using a sandwich ELISA format, instead of a whole cell direct ELISA 
we were unable to detect C. difficile cells (data not shown).  The simplest explanation for this 
is that the HMW SlpA biomarker is not surface exposed in anaerobically grown lab cultures of 
C. difficile 630 and that the whole cell direct ELISAs used to characterise mAb521 binding are 
detecting SlpA which is exposed or released from C. difficile cells during the overnight non-
specific electrostatic adherence to the ELISA plate. However, as the assay conditions are 
aerobic this could also be a contributing factor in releasing SlpA. Therefore, in order to 
chemically expose the SlpA biomarker we modified the published glycine extraction method 
into a rapid 10 min two-step extraction (See Supporting Information).  The revised method 
was applied to various C. difficile cell numbers (104/ml- 109/ml) and purified SlpA before 
assaying the extract in a sandwich ELISA, using mAb521 for capture and a polyclonal antibody 
raised against purified SlpA (pAbSlpA-HRP) for detection (see Supporting Information). Using 
this sandwich ELISA set-up we were able to derive a LOD of 12.4 ng/ml against purified SlpA 
(Figure 6a) and detect SlpA released from a minimum of 1.7 x 106 cells/ml (Figure 6b). 
Conclusions 
This work describes the computational identification of a unique biomarker for C. difficile. The 
biomarker identified by the bioinformatics pipeline was predicted to be conserved in all C. 
difficile strains.  This was validated by screening a representative member of each of the 
known C. difficile SLTs against mAb521 in a direct ELISA format in order to assess the 
specificity of mAb521 independently.  This demonstrated mAb521 could, as predicted, bind 
each of the 12 SLTs of C. difficile and, by extrapolation of this representative model data, all 
C. difficile species.  Additionally the biomarker was predicted to be unique to C. difficile whilst 
not being represented in other bacteria.  In order to test this,mAb521 was screened using a 
direct ELISA against a subset of bacteria commonly found in stool samples.  As predicted by 
the bioinformatics pipeline, mAb521 showed minimal cross-reactivity to these faecal bacteria 
under these conditions.  Furthermore, mAb521 displayed negligible cross reactivity to species 
which have biomarker signatures most closely resembling that of SlpA, C. hiranonis and P. 
anaerobius, as well as the most closely related species to C. difficile, C. sordellii. 
 
This species-specific recognition of C. difficile by mAb521 makes it an ideal candidate for a 
diagnostic antibody.  It has been shown on average ~ 10-fold more vegetative cells (~4.75 x 
106 cells/ml) than spores are typically found in stool samples of patients with CDI 31.  The LOD 
of 1.7 x 106 cells/ml, calculated against C. difficile cells using our mAb521-pAbSlpA sandwich 
ELISA demonstrate that it has the capacity to detect C. difficile in clinically relevant levels 
found in stool samples.  In order to achieve these clinically relevant levels of detection against 
C. difficile cells, a sample pre-treatment using low pH glycine was required, taking 10 min.  The 
sample pre-treatment releases SlpA from the S-layer, exposing the SlpA biomarker such that 
it can interact with mAb521 in its active conformation of a 1:1 heterodimer composed of 
HMW SlpA : LMW SlpA.  Although the HMW biomarker is clearly not accessible on the surface 
of the bacteria under these aerobic diagnostic assay conditions, there remains the possibility 
the biomarker is surface exposed under the truly native anaerobic environment of the 
gastrointestinal tract, so the current data does not completely exclude the possibility of the 
biomarker being a suitable vaccine or drug target.  
The biomarker and antibodies developed are clearly appropriate for centralised laboratory 
analysis using conventional ELISA formats.  The main area of future work will to be apply the 
biomarker and mAb521 to new assay formats, which are amenable for use at the point of 
care, such as lateral flow assays enhanced with nanozymes 32. In addition, we believe it is 
important to validate the biomarker accessibility in a truly anaerobic model system. Future 
work will assess mab521 binding to whole C. difficile cells under anaerobic conditions.  If 
mAb521 can inhibit C. difficile adherence to host enterocytes by neutralising SlpA, the 
antibody may have potential as a neutralising therapeutic option.  Additionally, if the HMW 
biomarker is found to be surface accessible under anaerobic conditions, this gives the 
biomarker utility as a vaccination target. 
This work demonstrates the bioinformatics approach employed has the potential to locate 
epitopes ubiquitously expressed across an entire group of interest, whilst mitigating the 
likelihood of false positive detection by intelligently screening potential biomarkers against 
RefSeq data for “other non-target bacteria”.  From this work it is clear the biomarker 
“AKDGSTKEDQLVDALA” is a universal species identifier, which was successfully used to guide 
the production of a universal antibody, mAb521, against the species, C. difficile. In addition, 
mAb521, in conjunction with a polyclonal partner has both high sensitivity and specify to the 
biomarker.  A clinical study is planned in order to evaluate mAb521 detection of SlpA, as a 
direct comparator to the GDH EIA, in a two-step testing algorithm for C. difficile. 
 
The computational approach described here for biomarker identification could also be 
deployed against any Gram-positive or Gram-negative bacteria with sequences deposited in 
RefSeq. The team are pursuing further confirmatory targets in both categories. 
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The Supporting Information is available free of charge on the 
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Computational and experimental methods, bacterial strains used in this work and bioinformatics 
approach to biomarker identification. 
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Figures 
 
Figure 1:  Schematic representation of the C. difficile cell wall and SlpA processing.  (A) C. 
difficile cell wall - the two SLPs are shown, HMW SlpA (blue) and LMW SlpA (green). Other 
minor cell wall proteins are shown as ovals (grey).  (b)  The precursor protein SlpA showing 
the cleavage sites (lightning bolt) generating the signal peptide (white rectangle), the mature 
LMW SlpA (green rectangle) and HMW SlpA (blue rectangle). 
 
 Figure 2: Western blot analysis against whole cell lysates:  mAb521 (5 µg/ml) was tested for 
binding against whole cell lysates from the 12 SLTs, Ox575 and the closely related species C. 
hiranonis, C. sordellii, and P. anaerobius.    
 
Figure 3:  Whole cell direct ELISA using mAb521 against all SLTs:  mAb521 (100 ng/ml) was 
probed for binding against the 12 SLTs, Ox575 and the closely related species C. hiranonis, 
C. sordellii, and P. anaerobius.  The error bars show the standard deviation seen between the 
two replicates of each sample. 
 Figure 4:  Whole cell direct ELISA using mAb521 against faecal bacteria.  mAb521 (100 ng/ml) 
was probed for binding against the common faecal bacteria Escherichia coli, P.  aeruginosa, 
K. pneumoniae, C. perfringens, C. freundii, P.  mirabilis and E. faecalis.  C. difficile 630 was used 
as a positive control and PBS as a negative control.  The error bars show the standard 
deviation seen between the two replicates of each sample.   
 
 
Figure 5:  Using SPR to characterise the binding of mAb521 against purified SlpA.  The 
apparent equilibrium dissociation constant (KD) for mAb521 binding to SlpA was calculated at 
380 s.  R2 = 0.99 (inset) through duplicate titrations of mAb521 (250 nM – 0.65 nM) over SlpA 
(main figure).  Duplicate injections of PBS over SlpA served as negative controls.  The error 
bars show the standard deviation seen between the two replicates of each sample.  
 
Figure 6:  Determining the LOD of the sandwich ELISA.  (a) Sandwich ELISA against purified 
SlpA using mAb521/pAbSlpA.  R2 = 0.99.  (b)  Sandwich ELISA against rapid glycine extracted 
cells (109-104/ml), extracted for 10 min.  R2 = 0.99.  The error bars show the standard deviation 
seen between the two replicates of each sample. 
